EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic settingAditya Bardia,Francois-Clement Bidard,Patrick Neven,Guillermo Streich,Alberto J. Montero,Frederic Forget,Marie-Ange Mouret-Reynier,Joo Hyuk Sohn, Donatienne Taylor,Kathleen K. Harnden,Hung Khong, Judit Kocsis,Florence Dalenc,Patrick Dillon,Sunil Babu,Simon Waters,Ines Deleu,Jose Angel Garcia-Saenz,Emilio Bria,Marina Elena Cazzaniga,Philippe Aftimos,Javier Cortes,Giulia Tonini,Tarek Sahmoud, Nassir Habboubi, Krzysztof Grzegorzewski, Virginia KaklamaniCANCER RESEARCH（2023）引用 0|浏览27暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
